Volume 1, Issue 1 (Winter-Spring 2018)                   Mod Med Lab J 2018, 1(1): 17-22 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abdollahzadeh Estakhri M, Kavakeb P, Fathi D, Karimi G, Mohammadpour A, Rahbar M. An Investigation of the Relationship between Beta-2 Microglobulin (β2M) and Inflammatory Factors (Serum Levels of CRP and Albumin) and High Density Lipoproteins (HDL) in Hemodialysis Patients. Mod Med Lab J 2018; 1 (1) :17-22
URL: http://modernmedlab.com/article-1-38-en.html
Abstract:   (6558 Views)

Background and Objective: Beta-2 Microglobulin (β2M) is a middle molecular weight uremic toxin. Lack of β2M removal leads to β2M accumulation and amyloidosis in hemodialysis patients. The present research aims to determine the relationship between β2M and inflammatory factors, such as C-reactive protein (CRP), albumin, and high-density lipoprotein (HDL) in hemodialysis patients. 

Methods: Fifty-four hemodialysis patients were selected and their pre- and post-dialysis serum levels of β2M, CRP, albumin, and HDL, were measured.

Results: There was an obvious inverse relationship between β2M level and serum level of albumin, while no relationship was found between β2M and CRP or HDL.

Conclusion: According to the findings of this study, it was identified that inflammatory-induced increase in β2M level in dialysis patients leads to reduced serum albumin

Full-Text [PDF 470 kb]   (3574 Downloads)    
Type of Study: Original Research Article | Subject: Laboratory Methods

References
1. U.S. Renal Data System, USRDS 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; June 2000.
2. Locatelli F, D'Amico M, Cerņevskis H, Dainys B, Miglinas M, Luman M, et al. The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture. Nephrol Dial Transplant 2001;16(7):1338-42. [DOI:10.1093/ndt/16.7.1338] [PMID]
3. Schena FP. Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney Int 2000;57:S39–S45. [DOI:10.1046/j.1523-1755.2000.07407.x]
4. Haghighi AN, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant 2002 ;17(1):28-32. [DOI:10.1093/ndt/17.1.28] [PMID]
5. Floege J, Ketteler M. beta2-microglobulin-derived amyloidosis: an update. Kidney Int Suppl. 2001;78:S164-71. [DOI:10.1046/j.1523-1755.2001.59780164.x] [PMID]
6. Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD: an in-depth review. Adv Ren Replace Ther 2003;10(4):279-309. [DOI:10.1053/j.arrt.2003.11.003] [PMID]
7. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003;63(5):1934-43. [DOI:10.1046/j.1523-1755.2003.00924.x] [PMID]
8. Zoccali C, Tripepi G, and Mallamaci F. Dissecting Inflammation in ESRD: Do Cytokines and C -reactive protein have a Complementary Prognostic Value for Mortality in Dialysis Patients? J Am Soc Nephrol 2006;17(12 Suppl 3):S169-73. [DOI:10.1681/ASN.2006080910] [PMID]
9. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9(12):2368-76. [PMID]
10. Bernier GM, Conrad ME, Catabolism of human beta-2-microglobulin by the rat kidney. Am J Physiol 1969;217(5):1359-62. [DOI:10.1152/ajplegacy.1969.217.5.1359] [PMID]
11. Edwards LC, Helderman JH, Hamm LL, Ludwin D, Gailiunas P Jr, Hull AR. Noninvasive monitoring of renal transplant function by analysis of beta2-microglobulin. Kidney Int 1983;23(5):767-70. [DOI:10.1038/ki.1983.92] [PMID]
12. Gotch F, Levin N, Zasuwa G, Tayeb J. Kinetics of beta-2-microglobulin in hemodialysis. Contrib Nephrol 1989;74:132-8. [DOI:10.1159/000417482] [PMID]
13. Carreno MP, Rousseau Y, Poignet JL, Jahns G, Cholley B, Kazatchkine MD. Dissociation between beta-2-microglobulin and cytokines in hemodialyzed patients. Nephrol Dial Transplant 1997;12(11):2365-74. [DOI:10.1093/ndt/12.11.2365] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Modern Medical Laboratory Journal